X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer

NCT02838238 | Unknown Phase 2

• 1 other identifier: PUMCH-BREAST-X in Elder
• Study Type: interventional
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Our study is a prospective, randomized phase II clinical trial, to compare the efficacy and safety profiles of single X versus placebo as adjuvant chemotherapy regimens for elder breast cancer patients.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (2)

• Disease-free survival

  5 years

• Adverse event rate (CTCAE v. 3.0)

  5 years

Secondary Outcomes (1)

• Overall survival

  5 years

Study Arms (2)

X

EXPERIMENTAL

Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles

Drug: Capecitabine

Placebo

PLACEBO COMPARATOR

Placebo, bid, po, d1-14, every 3 weeks for 6 cycles

Drug: Placebo

Interventions

Capecitabine DRUG

X

Placebo DRUG

Placebo

Eligibility Criteria

• Age: 70 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Age \>= 70 years old.
• Performance status (Karnofsky index) \>= 80.
• Histological diagnosis of invasive breast cancer (T3-T4,N0-1,M0). Tumor must bu hormone receptor negative. Time window between surgery and study randomization must be less than 60 days.
• Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected.
• Status of hormone receptors, HER2 status, Ki-67 index and p53 in primary tumour. ER and PR negative. And patients with positive HER-2 status should revceive the standard anti-targeted therapy.
• Written informed consent. Patients are able to comply with treatment and study follow-up.
• Patients must not present evidence of metastatic disease.
• Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).
• Laboratory results (within 14 days prior to randomization):
• Hematology: neutrophils \>= 2.0x10\^9/l; platelets \>= 100x10\^9/l; hemoglobin \>= 10 mg/dl; Hepatic function: total bilirubin \<= 1 upper normal limit (UNL); SGOT and SGPT \<= 2.5 UNL; alkaline phosphatase \<= 2.5 UNL. If values of SGOT and SGPT \> 1.5 UNL are associated to alkaline phosphatase \> 2.5 UNL, patient is not eligible; Renal function: creatinine \<= 175 mmol/l (2 mg/dl); creatinine clearance \>= 60 ml/min.
• ·Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests: as clinically indicated.

You may not qualify if:

• Prior systemic therapy for breast cancer.Or prior therapy with capecitabine for any malignancy.
• Prior radiotherapy for breast cancer.
• Bilateral invasive breast cancer.
• Any T4 or N2-3 or M1 tumour.
• Pre-existing grade \>= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria version 2.0 \[NCI CTC v-2.0\]).
• Any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled HA or high risk arrhythmias.
• History of neurological or psychiatric disorders, which could preclude the patients from free informed consent.
• Active uncontrolled infection.
• Active peptic ulcer; unstable diabetes mellitus.
• Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.
• Chronic treatment with corticosteroids.
• Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis treatment or for prevention. These treatments must stop before randomisation.
• Concomitant treatment with other investigational products; participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.
• Concomitant treatment with another therapy for cancer.
• Males.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (1)

Dept. Breast Surgery, PUMCH

Beijing, Beijing Municipality, 100730, China

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Capecitabine

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Central Study Contacts

Yan Lin, Doctor

CONTACT

+86-10-69152700; birds90@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief of Dept. Breast Surgery, Professor

Study Record Dates

• First Submitted: July 17, 2016
• First Posted: July 20, 2016
• Study Start: January 1, 2014
• Primary Completion: January 1, 2020
• Last Updated: July 20, 2016

Record last verified: 2016-07

Locations

CN (1)